DOV KADMON to Genetic Vectors
This is a "connection" page, showing publications DOV KADMON has written about Genetic Vectors.
Connection Strength
0.364
-
Suicide gene therapy for prostate cancer using a replication-deficient adenovirus containing the herpesvirus thymidine kinase gene. World J Urol. 2000 Apr; 18(2):125-9.
Score: 0.125
-
GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin Cancer Res. 2011 Nov 15; 17(22):7174-82.
Score: 0.069
-
Virus specific immune responses after human neoadjuvant adenovirus-mediated suicide gene therapy for prostate cancer. Eur Urol. 2005 Jul; 48(1):153-61.
Score: 0.044
-
Gene therapy for prostate cancer. Urology. 2001 Jan; 57(1):8-16.
Score: 0.033
-
Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. J Urol. 2000 Jun; 163(6):1747-50.
Score: 0.031
-
IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer. Cancer Gene Ther. 2007 Oct; 14(10):819-27.
Score: 0.013
-
Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys. 2004 Apr 01; 58(5):1520-9.
Score: 0.010
-
Gene therapy for prostate cancer. Expert Rev Anticancer Ther. 2002 Jun; 2(3):309-21.
Score: 0.009
-
Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--a preliminary report. Int J Radiat Oncol Biol Phys. 2001 Nov 01; 51(3):605-13.
Score: 0.009
-
Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther. 2001 Nov 01; 12(16):1955-67.
Score: 0.009
-
In vivo surgical resection plus adjuvant gene therapy in the treatment of mammary and prostate cancer. Mol Ther. 2001 Apr; 3(4):500-6.
Score: 0.008
-
Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras+myc-induced carcinomas in the mouse prostate reconstitution model system. Cancer Res. 1993 Oct 01; 53(19):4461-5.
Score: 0.005